Berenberg analyst Henry Tarr upgrades BP (NYSE:BP) from Hold to Buy.
Berenberg Upgrades BP to Buy
Berenberg analyst Henry Tarr upgrades BP (NYSE:BP) from Hold to Buy.
Related Posts
Where Biohaven Pharma Hldgs Stands With Analysts
Analysts have provided the following ratings for Biohaven Pharma Hldgs (NYSE:BHVN) within the last quarter:
Marker Therapeutics Awarded $13.1 Million Grant from the Cancer Prevention and Research Institute of Texas
Marker Therapeutics, Inc. (NASDAQ:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and